CJC-1295 no DAC (Mod GRF 1-29)

GHRH Analog & Somatotropic Signaling Research Compound

Product Overview CJC-1295 (no DAC), also frequently identified as Modified GRF (1-29), is a synthetic research peptide. It serves as a tetrasubstituted analog of the endogenous Growth Hormone-Releasing Hormone (GHRH 1-29). This specific modification is engineered to increase both receptor affinity and metabolic stability without the use of a Drug Affinity Complex (DAC). In laboratory settings, it functions by binding to the GHRH receptor, triggering adenylate cyclase and cAMP signaling to activate somatotropic pathways.

Key Research Applications

• Pharmacokinetic Analysis: Utilized as a primary model for investigating the absorption, distribution, and stability of modified GHRH analogs.

• Pituitary Receptor Regulation: Employed to examine the mechanisms governing pituitary receptor sensitivity and hormonal signaling.

• Somatotropic Signaling: Targeted in studies exploring the downstream effects of GHRH receptor activation on growth hormone production.

• Signal Transduction: Used to map adenylate cyclase and cAMP-mediated signaling cascades in experimental cellular models.

---

Why Researchers Choose CJC-1295 (no DAC)

• Enhanced Molecular Stability: The tetrasubstituted design provides a robust alternative to native GHRH for prolonged experimental observation.

• Optimized Receptor Affinity: Engineered for high specificity to the GHRH receptor, ensuring focused activation of somatotropic pathways.

• Analytical Grade Purity: Synthesized to a verified 99% HPLC purity for reliable, high-fidelity research data.

• Stable Lyophilized Format: Supplied as a lyophilized powder to preserve chemical integrity and extend shelf life during laboratory storage.

---

Technical Specifications Molecular Formula: C152_H252_​N44_​O42​

Molecular Weight: 3367.9 g/mol

CAS Number: 863288-34-0

Sequence: Tetrasubstituted analog of GHRH (1-29)

Purity: $\ge 99\%$

Research Notice: CJC-1295 no DAC (Mod GRF 1-29) is strictly for laboratory and scientific research use only. It is not approved for human or animal consumption, medical treatment, or therapeutic use.

References:

1. Frohman LA et al., Endocr Rev, 2001;22(6):606–648

2. Ip E et al., Endocrinology, 2005;146(7):3060–3066

3. Momany FA et al., Endocrinology, 1981;108(1):31–39